We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LAMZEDE (Chiesi Australia Pty Ltd)
Product name
LAMZEDE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
195 (255 working days)
Active ingredients
velmanase alfa
Registration type
NCE/ NBE
Indication
Enzyme replacement therapy for the treatment of non-central nervous system manifestations in patients with alpha-mannosidosis.
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.